Novel biomarkers in cardiovascular disease: Research tools or ready for personalized medicine?

Cardiology in Review

Volumn 20, Issue 3, 2012, Pages 111-117

  Stratz, Christian ^a   Amann, Michael ^a   Berg, David D ^b   Morrow, David A ^b   Neumann, Franz Josef ^a   Hochholzer, Willibald ^a,b  

^a UNIVERSITY HEART CENTER FREIBURG BAD KROZINGEN   (Germany)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

coronary heart disease; heart failure; personalized medicine; risk stratification; therapy stratification

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ADIPONECTIN; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CHOLINE; COPEPTIN; CREATINE KINASE MB; GELATINASE B; GROWTH DIFFERENTIATION FACTOR 15; HEART TYPE FATTY ACID BINDING PRTOEIN; HIGH SENSITIVITY CARDIAC TROPONIN; INTERLEUKIN 6; ISCHEMIA MODIFIED ALBUMIN; MYELOID RELATED PROTEIN 8; MYELOPEROXIDASE; MYOGLOBIN; PLACENTAL GROWTH FACTOR; PREGNANCY ASSOCIATED PLASMA PROTEIN A; PROTEIN TYROSINE KINASE; SECRETORY PHOSPHOLIPASE A2; SOLUBLE FMS LIKE TYROSINE KINASE 1; TROPONIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANALYTIC METHOD; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL DECISION MAKING; CONCENTRATION (PARAMETERS); DISEASE COURSE; HUMAN; INFLAMMATION; ISCHEMIC HEART DISEASE; PERSONALIZED MEDICINE; PREDICTIVE VALUE; REVIEW; SENSITIVITY AND SPECIFICITY;

AGED; BIOLOGICAL MARKERS; BIOMEDICAL RESEARCH; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; EARLY DIAGNOSIS; FEMALE; GLYCOPEPTIDES; GROWTH DIFFERENTIATION FACTOR 15; HUMANS; INDIVIDUALIZED MEDICINE; MALE; MIDDLE AGED; PEROXIDASE; PROGNOSIS; TROPONIN; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 84859650028     PISSN: 10615377     EISSN: 15384683     Source Type: Journal    
DOI: 10.1097/CRD.0b013e31824394e1     Document Type: Review

References (95)

1. Apple FS, Wu AH, Mair J, et al.; Committee on Standardization of Markers of Cardiac Damage of the IFCC. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem. 2005;51:810-824. (Pubitemid 40577917)
2. Libby P, Theroux P. Pathophysiology of coronary artery disease. Circulation. 2005;111:3481-3488. (Pubitemid 40923403)
3. Hochholzer W, Morrow DA, Giugliano RP. Novel biomarkers in cardiovascular disease: update 2010. Am Heart J. 2010;160:583-594.
4. Jaffe AS. Cardiovascular biomarkers: the state of the art in 2006. Clin Chim Acta. 2007;381:9-13. (Pubitemid 46719140)
5. Jaffe AS, Babuin L, Apple FS. Biomarkers in acute cardiac disease: the present and the future. J Am Coll Cardiol. 2006;48:1-11. (Pubitemid 44202476)
6. Morrow DA, de Lemos JA. Benchmarks for the assessment of novel cardiovascular biomarkers. Circulation. 2007;115:949-952. (Pubitemid 46328287)
7. Anderson JL, Adams CD, Antman EM, et al.; American College of Cardiology; American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction); American College of Emergency Physicians; Society for Cardiovascular Angiography and Interventions; Society of Thoracic Surgeons; American Association of Cardiovascular and Pulmonary Rehabilitation; Society for Academic Emergency Medicine. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation. 2007;116:e148-e304.
8. Thygesen K, Alpert JS, White HD, et al.; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Circulation. 2007;116:2634-2653.
9. Morrow DA, Cannon CP, Jesse RL, et al.; National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Circulation. 2007;115:e356-e375.
10. Macrae AR, Kavsak PA, Lustig V, et al. Assessing the requirement for the 6-hour interval between specimens in the American Heart Association Classification of Myocardial Infarction in Epidemiology and Clinical Research Studies. Clin Chem. 2006;52:812-818. (Pubitemid 43673258)
11. Keller T, Zeller T, Peetz D, et al. Sensitive troponin I assay in early diagnosis of acute myocardial infarction. N Engl J Med. 2009;361:868-877.
12. Apple FS. A new season for cardiac troponin assays: it's time to keep a scorecard. Clin Chem. 2009;55:1303-1306.
13. Wu AH, Jaffe AS. The clinical need for high-sensitivity cardiac troponin assays for acute coronary syndromes and the role for serial testing. Am Heart J. 2008;155:208-214.
14. Wu AH, Fukushima N, Puskas R, et al. Development and preliminary clinical validation of a high sensitivity assay for cardiac troponin using a capillary flow (single molecule) fluorescence detector. Clin Chem. 2006;52:2157-2159.
15. Wilson SR, Sabatine MS, Braunwald E, et al. Detection of myocardial injury in patients with unstable angina using a novel nanoparticle cardiac troponin I assay: observations from the PROTECT-TIMI 30 Trial. Am Heart J. 2009;158:386-391.
16. Giannitsis E, Becker M, Kurz K, et al. High-sensitivity cardiac troponin T for early prediction of evolving non-ST-segment elevation myocardial infarction in patients with suspected acute coronary syndrome and negative troponin results on admission. Clin Chem. 2010;56:642-650.
17. Januzzi JL Jr, Bamberg F, Lee H, et al. High-sensitivity troponin T concentrations in acute chest pain patients evaluated with cardiac computed tomography. Circulation. 2010;121:1227-1234.
18. Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial infarction with sensitive cardiac troponin assays. N Engl J Med. 2009;361:858-867.
19. Edelstein A, Fink D, Musch M, et al. Protective effects of nonionic triblock copolymers on bile acid-mediated epithelial barrier disruption. Shock. 2011;36:451-457.
20. Bonaca M, Scirica B, Sabatine M, et al. Prospective evaluation of the prognostic implications of improved assay performance with a sensitive assay for cardiac troponin I. J Am Coll Cardiol. 2010;55:2118-2124.
21. Kavsak PA, Wang X, Ko DT, et al. Short- and long-term risk stratification using a next-generation, high-sensitivity research cardiac troponin I (hscTnI) assay in an emergency department chest pain population. Clin Chem. 2009;55:1809-1815.
22. Latini R, Masson S, Anand IS, et al.; Val-HeFT Investigators. Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation. 2007;116:1242-1249.
23. Omland T, de Lemos JA, Sabatine MS, et al.; Prevention of Events with Angiotensin Converting Enzyme Inhibition (PEACE) Trial Investigators. A sensitive cardiac troponin T assay in stable coronary artery disease. N Engl J Med. 2009;361:2538-2547.
24. de Lemos JA, Drazner MH, Omland T, et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA. 2010;304:2503-2512.
25. deFilippi CR, de Lemos JA, Christenson RH, et al. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA. 2010;304:2494-2502.
26. Schulz O, Reinicke M, Berghoefer GH, et al. High-sensitive cardiac troponin I (hs-cTnI) values in patients with stable cardiovascular disease: an initial foray. Clin Chim Acta. 2010;411:812-817.
27. Eggers KM, Jaffe AS, Lind L, et al. Value of cardiac troponin I cutoff concentrations below the 99th percentile for clinical decision-making. Clin Chem. 2009;55:85-92.
28. Venge P, Johnston N, Lindahl B, et al. Normal plasma levels of cardiac troponin I measured by the high-sensitivity cardiac troponin I access prototype assay and the impact on the diagnosis of myocardial ischemia. J Am Coll Cardiol. 2009;54:1165-1172.
29. Hochholzer W, Buettner HJ, Trenk D, et al. New definition of myocardial infarction: impact on long-term mortality. Am J Med. 2008;121:399-405. (Pubitemid 351626008)
30. Pell JP, Simpson E, Rodger JC, et al. Impact of changing diagnostic criteria on incidence, management, and outcome of acute myocardial infarction: retrospective cohort study. BMJ. 2003;326:134-135. (Pubitemid 36135567)
31. Trevelyan J, Needham EW, Smith SC, et al. Impact of the recommendations for the redefinition of myocardial infarction on diagnosis and prognosis in an unselected United Kingdom cohort with suspected cardiac chest pain. Am J Cardiol. 2004;93:817-821. (Pubitemid 38429589)
32. Dargie H. Myocardial infarction: redefined or reinvented? Heart. 2002;88:1-3. (Pubitemid 34664983)
33. Richards AM, Lainchbury JG, Nicholls MG. Unsatisfactory redefinition of myocardial infarction. Lancet. 2001;357:1635-1636. (Pubitemid 32568231)
34. Podrez EA, Schmitt D, Hoff HF, et al. Myeloperoxidase-generated reactive nitrogen species convert LDL into an atherogenic form in vitro. J Clin Invest. 1999;103:1547-1560.
35. Naruko T, Ueda M, Haze K, et al. Neutrophil infiltration of culprit lesions in acute coronary syndromes. Circulation. 2002;106:2894-2900. (Pubitemid 35424738)
36. Sugiyama S, Okada Y, Sukhova GK, et al. Macrophage myeloperoxidase regulation by granulocyte macrophage colony-stimulating factor in human atherosclerosis and implications in acute coronary syndromes. Am J Pathol. 2001;158:879-891. (Pubitemid 32221781)
37. Buffon A, Biasucci LM, Liuzzo G, et al. Widespread coronary inflammation in unstable angina. N Engl J Med. 2002;347:5-12. (Pubitemid 34728951)
38. Zhang R, Brennan ML, Fu X, et al. Association between myeloperoxidase levels and risk of coronary artery disease. JAMA. 2001;286:2136-2142. (Pubitemid 34041599)
39. Meuwese MC, Stroes ES, Hazen SL, et al. Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol. 2007;50:159-165. (Pubitemid 47002189)
40. Ndrepepa G, Braun S, Mehilli J, et al. Myeloperoxidase level in patients with stable coronary artery disease and acute coronary syndromes. Eur J Clin Invest. 2008;38:90-96. (Pubitemid 351143413)
41. Eggers KM, Dellborg M, Johnston N, et al. Myeloperoxidase is not useful for the early assessment of patients with chest pain. Clin Biochem. 2010;43:240-245.
42. Lobbes MB, Kooi ME, Lutgens E, et al. Leukocyte counts, myeloperoxidase, and pregnancy-associated plasma protein a as biomarkers for cardiovascular disease: towards a multi-biomarker approach. Int J Vasc Med. 2010;2010:726207.
43. Baldus S, Heeschen C, Meinertz T, et al.; CAPTURE Investigators. Myeloperoxidase serum levels predict risk in patients with acute coronary syndromes. Circulation. 2003;108:1440-1445.
44. Mocatta TJ, Pilbrow AP, Cameron VA, et al. Plasma concentrations of myeloperoxidase predict mortality after myocardial infarction. J Am Coll Cardiol. 2007;49:1993-2000. (Pubitemid 46734639)
45. Morrow DA, Sabatine MS, Brennan ML, et al. Concurrent evaluation of novel cardiac biomarkers in acute coronary syndrome: myeloperoxidase and soluble CD40 ligand and the risk of recurrent ischaemic events in TACTICS-TIMI 18. Eur Heart J. 2008;29:1096-1102. (Pubitemid 351844877)
46. Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med. 2003;349:1595-1604. (Pubitemid 37288567)
47. Mitchell AM, Garvey JL, Kline JA. Multimarker panel to rule out acute coronary syndromes in low-risk patients. Acad Emerg Med. 2006;13:803-806. (Pubitemid 43928650)
48. McCann CJ, Glover BM, Menown IB, et al. Investigation of a multimarker approach to the initial assessment of patients with acute chest pain. Adv Ther. 2009;26:531-534.
49. Scirica BM, Sabatine MS, Jarolim P, et al. Assessment of multiple cardiac biomarkers in non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 trial. Eur Heart J. 2011;32:697-705.
50. Shih J, Datwyler SA, Hsu SC, et al. Effect of collection tube type and preanalytical handling on myeloperoxidase concentrations. Clin Chem. 2008;54:1076-1079. (Pubitemid 351793416)
51. Baldus S, Rudolph V, Roiss M, et al. Heparins increase endothelial nitric oxide bioavailability by liberating vessel-immobilized myeloperoxidase. Circulation. 2006;113:1871-1878. (Pubitemid 43739399)
52. Struck J, Morgenthaler NG, Bergmann A. Copeptin, a stable peptide derived from the vasopressin precursor, is elevated in serum of sepsis patients. Peptides. 2005;26:2500-2504. (Pubitemid 41676723)
53. Mutlu GM, Factor P. Role of vasopressin in the management of septic shock. Intensive Care Med. 2004;30:1276-1291. (Pubitemid 38951709)
54. Katan M, Morgenthaler N, Widmer I, et al. Copeptin, a stable peptide derived from the vasopressin precursor, correlates with the individual stress level. Neuro Endocrinol Lett. 2008;29:341-346.
55. Reichlin T, Hochholzer W, Stelzig C, et al. Incremental value of copeptin for rapid rule out of acute myocardial infarction. J Am Coll Cardiol. 2009;54:60-68.
56. Keller T, Tzikas S, Zeller T, et al. Copeptin improves early diagnosis of acute myocardial infarction. J Am Coll Cardiol. 2010;55:2096-2106.
57. Khan SQ, Dhillon OS, O'Brien RJ, et al. C-terminal provasopressin (copeptin) as a novel and prognostic marker in acute myocardial infarction: Leicester Acute Myocardial Infarction Peptide (LAMP) study. Circulation. 2007;115:2103-2110. (Pubitemid 46659061)
58. Schnabel RB, Schulz A, Messow CM, et al. Multiple marker approach to risk stratification in patients with stable coronary artery disease. Eur Heart J. 2010;31:3024-3031.
59. Neuhold S, Huelsmann M, Strunk G, et al. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease. J Am Coll Cardiol. 2008;52:266-272. (Pubitemid 351957847)
60. Voors AA, von Haehling S, Anker SD, et al.; OPTIMAAL Investigators. C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study. Eur Heart J. 2009;30:1187-1194.
61. Alehagen U, Dahlström U, Rehfeld JF, et al. Association of copeptin and N-terminal proBNP concentrations with risk of cardiovascular death in older patients with symptoms of heart failure. JAMA. 2011;305:2088-2095.
62. Masson S, Latini R, Carbonieri E, et al.; GISSI-HF Investigators. The predictive value of stable precursor fragments of vasoactive peptides in patients with chronic heart failure: data from the GISSI-heart failure (GISSI-HF) trial. Eur J Heart Fail. 2010;12:338-347.
63. de Kruif MD, Lemaire LC, Giebelen IA, et al. The influence of corticosteroids on the release of novel biomarkers in human endotoxemia. Intensive Care Med. 2008;34:518-522. (Pubitemid 351623033)
64. Bhandari SS, Loke I, Davies JE, et al. Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci. 2009;116:257-263.
65. Shi Y, Massagué J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell. 2003;113:685-700. (Pubitemid 36724933)
66. Bauskin AR, Brown DA, Kuffner T, et al. Role of macrophage inhibitory cytokine-1 in tumorigenesis and diagnosis of cancer. Cancer Res. 2006;66:4983-4986. (Pubitemid 43852864)
67. Ago T, Sadoshima J. GDF15, a cardioprotective TGF-beta superfamily protein. Circ Res. 2006;98:294-297.
68. Kempf T, Eden M, Strelau J, et al. The transforming growth factor-beta superfamily member growth-differentiation factor-15 protects the heart from ischemia/reperfusion injury. Circ Res. 2006;98:351-360.
69. Wollert KC, Kempf T, Peter T, et al. Prognostic value of growth-differentiation factor-15 in patients with non-ST-elevation acute coronary syndrome. Circulation. 2007;115:962-971. (Pubitemid 46328289)
70. Khan SQ, Ng K, Dhillon O, et al. Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction. Eur Heart J. 2009;30:1057-1065.
71. Eggers KM, Kempf T, Allhoff T, et al. Growth-differentiation factor-15 for early risk stratification in patients with acute chest pain. Eur Heart J. 2008;29:2327-2335.
72. Eitel I, Blase P, Adams V, et al. Growth-differentiation factor 15 as predictor of mortality in acute reperfused ST-elevation myocardial infarction: insights from cardiovascular magnetic resonance. Heart. 2011;97:632-640.
73. Bonaca MP, Morrow DA, Braunwald E, et al. Growth differentiation factor-15 and risk of recurrent events in patients stabilized after acute coronary syndrome: observations from PROVE IT-TIMI 22. Arterioscler Thromb Vasc Biol. 2011;31:203-210.
74. Wollert KC, Kempf T, Lagerqvist B, et al. Growth differentiation factor 15 for risk stratification and selection of an invasive treatment strategy in non ST-elevation acute coronary syndrome. Circulation. 2007;116:1540-1548. (Pubitemid 47511417)
75. Anand IS, Kempf T, Rector TS, et al. Serial measurement of growth-differentiation factor-15 in heart failure: relation to disease severity and prognosis in the Valsartan Heart Failure Trial. Circulation. 2010;122:1387-1395.
76. Stahrenberg R, Edelmann F, Mende M, et al. The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction. Eur J Heart Fail. 2010;12:1309-1316.
77. Wang F, Guo Y, Yu H, et al. Growth differentiation factor 15 in different stages of heart failure: potential screening implications. Biomarkers. 2010;15:671-676.
78. Edelstein BL. Training new dental health providers in the United States. J Public Health Dent. 2011;71(suppl 2):S3-S8.
79. Duan M, Kazmierski WM, Chong PY, et al. Discovery of novel pyridyl carboxamides as potent CCR5 antagonists and optimization of their pharmacokinetic profile in rats. Bioorg Med Chem Lett. 2011;21:6470-6475.
80. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843. (Pubitemid 30165206)
81. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973-979. (Pubitemid 27152782)
82. Ridker PM, Cushman M, Stampfer MJ, et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998;97:425-428. (Pubitemid 28090212)
83. Koenig W, Sund M, Fröhlich M, et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation. 1999;99:237-242. (Pubitemid 29056365)
84. Elliott P, Chambers JC, Zhang W, et al. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. JAMA. 2009;302:37-48.
85. Ridker PM, Danielson E, Fonseca FA, et al.; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195-2207.
86. Heart Protection Study Collaborative G. C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20 536 patients in the Heart Protection Study. Lancet. 2011;377:469-476.
87. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-676. (Pubitemid 36749215)
88. Shibuya M. Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis. 2006;9:225-230; discussion 231.
89. Chung NA, Lydakis C, Belgore F, et al. Angiogenesis in myocardial infarction. An acute or chronic process? Eur Heart J. 2002;23:1604-1608. (Pubitemid 35221565)
90. Heeschen C, Dimmeler S, Fichtlscherer S, et al.; CAPTURE Investigators. Prognostic value of placental growth factor in patients with acute chest pain. JAMA. 2004;291:435-441.
91. Iwama H, Uemura S, Naya N, et al. Cardiac expression of placental growth factor predicts the improvement of chronic phase left ventricular function in patients with acute myocardial infarction. J Am Coll Cardiol. 2006;47: 1559-1567.
92. Khurana R, Moons L, Shafi S, et al. Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation. Circulation. 2005;111:2828-2836. (Pubitemid 40791556)
93. Maglione D, Guerriero V, Viglietto G, et al. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Proc Natl Acad Sci U S A. 1991;88:9267-9271. (Pubitemid 21915612)
94. Hochholzer W, Reichlin T, Stelzig C, et al. Impact of soluble fms-like tyrosine kinase-1 and placental growth factor serum levels for risk stratification and early diagnosis in patients with suspected acute myocardial infarction. Eur Heart J. 2011;32:326-335.
95. Kapur NK, Heffernan KS, Yunis AA, et al. Elevated soluble fms-like tyrosine kinase-1 levels in acute coronary occlusion. Arterioscler Thromb Vasc Biol. 2011;31:443-450.